Related Experiment Video
Updated: Jun 8, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
DNA methyltransferase inhibition may limit cancer cell growth by disrupting ribosome biogenesis
1Cancer Research Centre and Dept. of Molecular Biology, Medical Biochemistry and Pathology, Laval University, Quebec, Canada. Tom.Moss@crhdq.ulaval.ca
Abstract:
"Mutations" in the pattern of CpG methylation imprinting of the human genome have been correlated with a number of diseases including cancer. In particular, aberrant imprinting of tumor suppressor genes by gain of CpG methylation has been observed in many cancers and thus represents an important alternative pathway to gene "mutation" and tumor progression. Inhibitors of DNA methylation display therapeutic effects in the treatment of certain cancers, and it has been assumed these effects are due to the reversal of "mutant" gene imprinting. However, significant reactivation of imprinted tumor suppressor genes is rarely observed in vivo following treatment with DNA methylation inhibitors. A recent study revealed an unexpected requirement for CpG methylation in the synthesis and assembly of the ribosome, an essential function for cell growth and proliferation. As such, the data provide an unforeseen explanation of the action of DNA methylation inhibitors in restricting cancer cell growth.
Insights
CpG methylation is crucial for ribosome synthesis, explaining how DNA methylation inhibitors restrict cancer cell growth. This finding offers a new perspective on cancer therapy beyond reversing aberrant gene imprinting.
Area of Science:
- Epigenetics
- Cancer Biology
- Molecular Biology
Background:
- Aberrant CpG methylation imprinting is linked to diseases like cancer, particularly in tumor suppressor genes.
- DNA methylation inhibitors show therapeutic effects in cancer, presumed to reverse aberrant imprinting.
Purpose of the Study:
- To investigate the mechanism of action for DNA methylation inhibitors in cancer treatment.
- To explore the role of CpG methylation beyond gene imprinting.
Main Methods:
- Analysis of CpG methylation patterns in human genomes.
- Assessment of DNA methylation inhibitor effects in cancer models.
- Investigation of cellular processes affected by DNA methylation.
Main Results:
- Significant reactivation of imprinted tumor suppressor genes in vivo is rarely observed after treatment with DNA methylation inhibitors.
- CpG methylation is unexpectedly required for ribosome synthesis and assembly.
- Cancer cell growth is restricted by DNA methylation inhibitors.
Conclusions:
- The therapeutic effects of DNA methylation inhibitors may stem from their impact on ribosome biogenesis rather than solely reversing aberrant gene imprinting.
- CpG methylation plays a critical role in essential cellular functions like proliferation.
- This study provides a novel explanation for the anti-cancer action of DNA methylation inhibitors.
More Related Videos
Related Concept Videos
Biosynthesis of Nucleic Acids
The Nucleolus
MicroRNAs
MicroRNAs
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation

